Specialty pharmaceutical and medical device firm Delcath Systems has presented the trial results of a Hepatic Chemosat Delivery System at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
The results were presented as an on-line abstract titled "single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma."
Uveal melanoma or ocular melanoma is a rare cancer of the eye with a very poor prognosis.
As per the study authors: "50% of patients develop distant disease, mainly in the liver (90%), with a mean survival of 6 months and 1-year survival rate of 15-20%."
In the trial, 20 patients received 34 treatments with Chemosat (1-3 treatments per patient) and radiologically two patients demonstrated stable disease for above three months and 13 patients had a partial response in the liver with complete responses in two patients.
According to the firm, nine deaths from disease progression occurred after a median of 264 days from the first procedure and 11 patients remain alive after a median of 280 days with one complete response ongoing at above one year.
Delcath Systems president and CEO Dr Jennifer Simpson said: "We are especially pleased to have these data shared with the thousands of oncology specialists from around the world who attend ASCO."
Chemosat received CE mark approval in Europe and is not approved in the US.